WALWORTH, WI, June 03, 2013 (Press-News.org) The 10th annual Silver & Black Series presented by the Chicago Scouts Association will take off on June 9th at Symonds/Puckett Field, Triton College in River Grove, Illinois. This year the underclassmen (2015s) will workout first on Sunday with the 2014 graduates taking the field on Monday. In September, Hampshire High School will host the Silver & Black Series with the 2016s working out on September 15th and the 2017s on September 22nd.
Player registration begins on Sunday, June 9 and Monday, June 10 at 8 AM with an expected first pitch beginning at 10 AM. Each team will play two games with each pitcher being held to a 15 pitch count/maximum per inning.
The Silver and Black Series is one of the top baseball events in the Midwest. The student-athletes who have exhibited superior skill on the baseball diamond and exceptional character off the diamond are invited annually to exhibit their talents amongst professional scouts and college coaches.
"The Silver & Black Series was an awesome experience, playing against the best in the Midwest. The exposure I receive was unbeatable. The fact that it does not cost anything just topped off the whole experience." says Louisville Cardinal recruit Colin Lyman.
The top high school baseball players from the Midwest have been invited to this quality event free of charge. The June 10th Silver & Black Series participants will also benefit with an invite to the Area Code tryouts, June 24th & 25th at Elgin Community College and Triton College. Players selected for the White Sox Area Code team will travel to Long Beach, California in August to compete in the prestigious New Balance Area Code Games.
Regynold Johnson, a University of Missouri recruit said, "Being a part of the Silver & Black Series was an excellent opportunity because not only was it free, but it also placed me in front of professional and collegiate scouts."
Standout participants earn the opportunity to travel to the New Balance Area Code Games in California. At this venue, the audience grows to a national level as MLB Scouts and college coaches from all over the nation are in attendance. An exceptional performance can unlock options for a young player from the professional ranks and academic institutions.
John Sarna, Director of the Silver & Black Series said, "The last 10 years with this program has been amazing. I am proud of the talent and quality this series showcases and appreciate the professionalism and effort of its alumni base.
Notable Silver & Black Series alumni include Cleveland Indian Zach McAllister, St. Louis Cardinals prospect Charlie Tilson, Louisville Cardinal Nick Burdi, and Virginia Tech Hokie Brendon Hayden.
This year the Silver & Black Series is sponsored by Mizuno USA and the Hoosier Bat Company.
The Silver and Black Series has established itself as the top baseball event in the Midwest. The student-athletes who have exhibited superior skill on the baseball diamond and exceptional character off the diamond are invited annually to exhibit their talents amongst professional scouts and college coaches. The Silver & Black Series is a platform step for those that aspire to baseball on a higher level. Standout participants earn the opportunity to travel to the New Balance Area Code Games in California. At this venue, the audience grows to a national level as MLB Scouts and college coaches from all over the nation are in attendance. An exceptional performance can unlock options for a young player from the professional ranks and academic institutions. Your hard work has gotten you this far. Work hard at the Silver & Black Series and see how far the path takes you.
Silver & Black Series Alumni Expected to Make a Presence at MLB's First-Year Player Draft as 2014s and 2015s Showcase their Talent Live June 9th & 10th
The 2013 edition of the Silver & Black Series is once again loaded with top baseball prospects from the Midwest. Several Silver & Black Series Alumni are projected to be selected in this week's MLB First-Year Player Draft, June 6th - 8th.
2013-06-03
ELSE PRESS RELEASES FROM THIS DATE:
"Worst Ever" Slam by Yahoo! Boosts Sales of New ThiPad Tablet Stand
2013-06-03
In their May 17th "Digital Crave" shopping blog, Yahoo! included the new ThiPad thigh-mounted tablet stand in a piece titled "The Worst iPad Accessories--Ever."
"And they did us a favor," says Jerry McTigue, creator of the ThiPad. "Because the hundreds of readers who went to the ThiPad.com website to see just how bad a product it was, actually discovered how good it was. And they started buying it."
McTigue believes that if the ThiPad can gain converts with horrible publicity like that, there's no telling what it would do if ...
Some patients with treatment-resistant colorectal cancers may have a new option
2013-06-02
PHILADELPHIA — A subset of colorectal cancers responds to anti-epidermal growth factor receptor (anti-EGFR) therapies, but develops resistance within months. Among cancers that develop resistance to anti-EGFR therapy, some showed overexpression of a gene called MET, according to a study published in the June issue of Cancer Discovery, a journal of the American Association for Cancer Research. Preliminary data published in this study showed human tumors with MET amplification, grown in mice, responded to MET inhibitor drugs.
The MET gene is known to be amplified in about ...
Addition of bevacizumab to initial treatment for brain tumors does not extend patients' lives
2013-06-02
Results of a randomized phase III clinical trial conducted by the Radiation Therapy Oncology Group (RTOG) determined that adding bevacizumab to initial treatment for glioblastoma (GBM) did not improve patient overall survival or progression-free survival,. Results were reported June 2 during the plenary session of the American Society of Clinical Oncology 2013 Annual Meeting.
Chicago, Illinois—GBM is the most common primary malignant brain tumor in adults and, despite treatment advances in recent years, the average survival of patients enrolled in clinical trials is ...
New cancer drug shows promise for treating advanced melanoma
2013-06-02
Researchers from UCLA's Jonsson Comprehensive Cancer Center report that a new drug in preliminary tests has shown promising results with very manageable side effects for treating patients with melanoma, the deadliest form of skin cancer.
The results were presented at the 2013 meeting of the American Society of Clinical Oncology today in Chicago by Dr. Antoni Ribas, professor of medicine in the UCLA division of hematology-oncology, who led the research. Following Ribas' presentation, the study was published online ahead of press in the New England Journal of Medicine. ...
Test helps target glioblastoma patients most likely to benefit from bevacizumab
2013-06-02
CHICAGO, IL – A new test may help identify newly diagnosed glioblastoma patients more likely to benefit from bevacizumab (Avastin®), according to new research from The University of Texas MD Anderson Cancer Center.
The results of the study were presented today at the annual meeting of the American Society of Clinical Oncology.
This study is associated with RTOG 0825, a large multi-center Phase III trial that evaluated the addition of bevacizumab to standard chemoradiation and maintenance temozolomide in treating newly diagnosed glioblastoma. Half of the participants ...
Combination of drugs produces dramatic tumor responses in advanced melanoma patients
2013-06-02
CHICAGO, JUNE 2, 2013 — The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published online on Sunday, June 2, in The New England Journal of Medicine and presented by Memorial Sloan-Kettering Cancer Center researchers at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Several patients experienced tumor shrinkage of more than 80 percent within ...
Bevacizumab offers no benefit for newly diagnosed glioblastoma, M.D. Anderson-led study finds
2013-06-02
Chicago, IL – The angiogenesis inhibitor bevacizumab (Avastin) failed to increase overall survival (OS) or statistically significant progression-free survival (PFS) for glioblastoma patients in the frontline setting, according to research led by researchers at The University of Texas MD Anderson Cancer Center.
The study was presented today on the plenary session of the American Society of Clinical Oncology 2013 Annual Meeting by Mark Gilbert, M.D., professor in MD Anderson's Department of Neuro-Oncology.
Glioblastoma is both the most common and lethal form of brain ...
US oncologists report high career satisfaction, yet many suffer symptoms of burnout
2013-06-02
CHICAGO -- Even though a majority of U.S. oncologists report satisfaction with their careers, many say they have experienced at least one symptom of burnout, a Mayo Clinic-led study has found. The study was released during the American Society of Clinical Oncology's annual meeting in Chicago.
"Oncology can be a tremendously rewarding area of medicine, but caring for patients with cancer is also demanding and stressful," says lead author Tait Shanafelt, M.D., a Mayo Clinic hematologist/oncologist. "Oncologists work long hours, supervise the administration of highly toxic ...
Abnormalities in HER2 gene found in wide variety of advanced cancers
2013-06-02
(CHICAGO) The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes 's expression — among them mutations, amplifications, substitutions, and translocations — have been found in 14 different advanced solid tumors.
The results of the study of more than 2,000 tumors, being presented at the annual meeting of the American Society of Clinical Oncology (ASCO), both surprised researchers and provided hope that some of these tumors might benefit from the three anti-HER2 therapies now in clinical use.
"No ...
Therapy that heats and destroys bone tumors eases patients' pain
2013-06-02
(CHICAGO) Patients with cancer that has spread to their bones are often treated with radiation therapy to reduce pain. But if that treatment doesn't work, or can't be used again, a second, effective option now exists. Results of a clinical trial on the new therapy, presented by a researcher at Jefferson's Kimmel Cancer Center, is being presented at the annual meeting of the American Society of Clinical Oncology (ASCO).
Mark Hurwitz, MD, Director of Thermal Oncology for the Department of Radiation Oncology at Thomas Jefferson University and Hospital reported that the treatment, ...
LAST 30 PRESS RELEASES:
Geographic bias in virus naming: Lessons from coronavirus show it’s better to act early
Cultured mini-organs reveal the weapons of aggressive bacteria
Centuries-old mercury pollution hidden in the ocean threatens arctic wildlife
Researchers identify how physical activity protects the brain—cell by cell—in Alzheimer's disease
The EU CAR-T Handbook released to advance clinical practice and education
Conservative oxygen therapy in mechanically ventilated critically ill adult patients
Molecular hopscotch boosts light upconversion
Prolonged use of desogestrel pill linked to small increased brain tumour risk
Doctors raise concern over rise in recreational ketamine use
New index ranks 917 European cities on urban design for health and well-being
Exposure to pollution during pregnancy linked with changes in fetal brain structures
New way of measuring blood pressure could be a lifeline for thousands of people
Famous Ice Age ‘puppies’ likely wolf cubs and not dogs, study shows
Leg amputation caused by arterial disease four times higher in disadvantaged areas
Researchers solve ultrasound imaging problem using seismology technique
Among new dads, 64% take less than two weeks of leave after baby is born
Decades-old mystery of AlCl dipole moment resolved
Stroke, dementia more common in people with biomarker of aging
Shorter telomeres linked to increased risk of age-related brain diseases
Calling for renewed Israeli-Palestinian health cooperation
Rutgers health researchers challenge FDA warning on common epilepsy drug
In the belly of the beast: massive clumps reveal star factories from a bygone era of the cosmos
NASA’s Webb ‘UNCOVERs’ galaxy population driving cosmic renovation
Is your gut microbiome a calorie ‘super harvester’?
Some dog breeds are more likely to get diarrhea
Structural brain differences found in kids who experienced prenatal Superstorm Sandy exposure
Mapping patient satisfaction across U.S. hospitals reveals the Midwest as the leading region
Ladybirds' complex colors may result from a combination of pigments and physical properties of their wingcase
Exposure to multiple extreme climate events during pregnancy may have a cumulative effect on child brain development
Single-material electronic skin gives robots the human touch
[Press-News.org] Silver & Black Series Alumni Expected to Make a Presence at MLB's First-Year Player Draft as 2014s and 2015s Showcase their Talent Live June 9th & 10thThe 2013 edition of the Silver & Black Series is once again loaded with top baseball prospects from the Midwest. Several Silver & Black Series Alumni are projected to be selected in this week's MLB First-Year Player Draft, June 6th - 8th.